There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevena (TRVN – Research Report) and Zealand Pharma (ZEAL – Research Report) with bullish sentiments.
Trevena (TRVN)
JMP Securities analyst Jason Butler reiterated a Buy rating on Trevena today and set a price target of $2.00. The company’s shares closed last Thursday at $0.24, close to its 52-week low of $0.18.
According to TipRanks.com, Butler ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trevena with a $2.75 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Zealand Pharma (ZEAL)
Needham analyst Joseph Stringer reiterated a Buy rating on Zealand Pharma today and set a price target of $32.00. The company’s shares closed last Thursday at $17.92.
According to TipRanks.com, Stringer is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zealand Pharma with a $32.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TRVN:
- Mizuho Securities Keeps Their Buy Rating on Wave Life Sciences (WVE)
- Needham Sticks to Their Buy Rating for Cellebrite DI (CLBT)
- Wellbeing Digital Sciences Inc. Changes Year-End
- Transaction in Own Shares
- Pinnacle Bankshares Corporation appoints Liberty University Dean and Former U.S. Congressman, Robert Hurt, to Board of Directors
